$3.85
1.53%
Nasdaq, Fri, Sep 27 2024
ISIN
US05479K1060
Symbol
AZYO
Sector
Industry

Aziyo Biologics Inc - Ordinary Shares - Class A Stock price

$3.85
-0.14 3.51% 1M
+0.70 22.22% 6M
+1.69 78.24% YTD
+2.57 200.78% 1Y
-3.65 48.67% 3Y
-13.15 77.35% 5Y
-13.15 77.35% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.06 1.53%
ISIN
US05479K1060
Symbol
AZYO
Sector
Industry

Key metrics

Market capitalization $133.18m
Enterprise Value $149.17m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.97
P/S ratio (TTM) P/S ratio 5.33
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -48.37%
Revenue (TTM) Revenue $24.99m
EBIT (operating result TTM) EBIT $-21.99m
Free Cash Flow (TTM) Free Cash Flow $-21.96m
Cash position $18.19m
EPS (TTM) EPS $-3.12
P/E forward negative
P/S forward 5.01
EV/Sales forward 5.61
Short interest 1.50%
Show more

Is Aziyo Biologics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Aziyo Biologics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
25 25
48% 48%
100%
- Direct Costs 14 14
54% 54%
58%
11 11
39% 39%
42%
- Selling and Administrative Expenses 25 25
19% 19%
100%
- Research and Development Expense 4.11 4.11
42% 42%
16%
-18 -18
10% 10%
-74%
- Depreciation and Amortization 3.55 3.55
6% 6%
14%
EBIT (Operating Income) EBIT -22 -22
9% 9%
-88%
Net Profit -71 -71
110% 110%
-285%

In millions USD.

Don't miss a Thing! We will send you all news about Aziyo Biologics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
about one year ago
SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET.
Neutral
GlobeNewsWire
about one year ago
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket
Neutral
Seeking Alpha
about one year ago
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023...
More Aziyo Biologics Inc - Ordinary Shares - Class A News

Company Profile

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.

Head office United States
CEO Charles Mills
Employees 54
Founded 2015
Website www.elutia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today